Oral Laquinimod Reduced MS Relapses
Links shared publicly online about this topic
AAN 2011: Laquinimod Reduces Relapses in Multiple Sclerosis
hcplive.com — “Study results show that oral laquinimod reduces the annual relapse rate in patients with relapsing-remitting multiple sclerosis.” View full resource at hcplive.com
Most Recently Shared on April 15, 2011 at 3:44 pm By:
#AAN2011 oral laquinimod reduces the annual relapse rate in patients with relapsing-remitting #multiplesclerosis http://hcp.lv/eBKzu6
Oral Laquinimod Reduced MS Relapses by 23% : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on April 13, 2011 at 9:38 pm By:
Bob Finn - Medical News Net Health News
In MS, 2 yrs of laquinimod reduced relapse rate and disability progression. @SherryBoschert reports. http://bit.ly/ij1iS3
Laquinimod Reduces Relapse Rate in Relapsing-Remitting MS --Doctors Lounge
doctorslounge.com — “Laquinimod Reduces Relapse Rate in Relapsing-Remitting MS --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on March 15, 2012 at 2:37 am By:
Laquinimod Reduces Relapse Rate in Relapsing-Remitting MS http://t.co/P7yOfY2C #Health #Medicine
Oral Laquinimod Reduced MS Relapses by 23% : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on April 13, 2011 at 7:27 pm By:
Miriam E. Tucker Patient Expert
RT @IntMedNews: Oral Laquinimod Reduced MS Relapses by 23% http://bit.ly/ibjpN5
Oral Pill Fingolimod Reduces Relapses And Disability Progression
medicalnewstoday.com — “Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod (FTY-720) in people with relapsing remitting multiple sclerosis (MS). The res” View full resource at medicalnewstoday.com
Most Recently Shared on October 1, 2009 at 1:48 pm By:
MedNewsToday: Oral Pill Fingolimod Reduces Relapses And Disability Progression: Drug manufacturer .. http://bit.ly/2S2X9O
AAN 2011: Oral Cladribine Reduces Relapses in MS Patients Who Failed Injectable Therapies
hcplive.com — “Results from the CLARITY study show cladribine reduces the relapse rate in multiple sclerosis patients who have failed other disease-modifying therapies.” View full resource at hcplive.com
Most Recently Shared on April 14, 2011 at 2:01 pm By:
#AAN2011 CLARITY study shows #cladribine reduces relapse rate in injection-intolerant #multiplesclerosis patients http://hcp.lv/dPBXxT
Dimethyl Fumarate Considerably Reduces MS Relapses And Disability Progression
medicalnewstoday.com — “240 mg of Dimethyl Fumarate (BG-12) taken orally two or three times a day showed reduced relapses by about half in patients with relapsing-remitting multiple sclerosis (PRMS) compared to those on” View full resource at medicalnewstoday.com
Most Recently Shared on October 22, 2011 at 8:05 pm By:
Dimethyl Fumarate Considerably Reduces MS Relapses And Disability Progression http://t.co/7Xlw5TiI #multiplesclerosis
Oral Laquinimod Demonstrated Sustained Efficacy And Safety In Patients With Multiple Sclerosis
medicalnewstoday.com — “Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced results from a 36-week active extension study evaluating two doses of laquinimod, an inves” View full resource at medicalnewstoday.com
Most Recently Shared on September 21, 2010 at 2:03 pm By:
Oral Laquinimod Demonstrated Sustained Efficacy And Safety In Patients With Multiple Sclerosis: Teva Pharmaceutica... http://mnt.to/f/3K5b
FDA Approves First Oral Drug To Reduce MS Relapses
medicalnewstoday.com — “The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 11:05 pm By:
MNT Drug Approvals Health News
FDA Approves First Oral Drug To Reduce MS Relapses http://mnt.to/3Khy #regulatory
FDA Approves First Oral Drug To Reduce MS Relapses
medicalnewstoday.com — “The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2010 at 2:37 pm By:
FDA Approves First Oral Drug To Reduce MS Relapses: The U.S. Food and Drug Administration has approved Gilenya cap... http://mnt.to/f/3Kdv
Phase 3 study of oral laquinimod for multiple sclerosis - ONA
oncologynurseadvisor.com — “Teva and Active Biotech announced initial results from their Phase 3 trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (MS).” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 9, 2010 at 3:38 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of oral laquinimod for multiple sclerosis http://goo.gl/fb/ZCvgE
Phase 3 study of oral laquinimod for multiple sclerosis - MPR
empr.com — “Teva and Active Biotech announced initial results from their Phase 3 trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (MS).” View full resource at empr.com
Most Recently Shared on December 9, 2010 at 3:47 pm By:
MPR News: Phase 3 study of oral laquinimod for multiple sclerosis: Teva and Active Biotech announced initial res... http://bit.ly/gOpFUX
Oral Drug to Reduce MS Relapses FDA Approved
disabled-world.com — “FDA has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS)” View full resource at disabled-world.com
Most Recently Shared on September 22, 2010 at 8:04 pm By:
Disabled World Health Advocate and Health News
Oral Drug to Reduce MS Relapses FDA Approved http://ff.im/-qXZCQ
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS TREATMENT SIGNIFICANTLY REDUCED DISEASE ACTIVITY AND DISABILITY PROGRESSION WHILE PROVIDING GOOD SAFETY AND TOLERABILITY
wallstreet-online.de — “Teva Announces Updated Time For Webcast To Discuss Study Results On April 12th, 01:00 a.m. CET- Phase III ALLEGRO study met primary endpoint and key secondary endpoints: o 23 percent reduction in annualized relapse ...” View full resource at wallstreet-online.de
Most Recently Shared on April 12, 2011 at 8:33 am By:
ORAL LAQUINIMOD FOR MULTIPLE SCLEROSIS TREATMENT SIGNIFICANTLY REDUCED DISEASE ACTIVITY AND DISABILITY PROGRESSI... http://bit.ly/fddGzF
Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis - Drugs.com MedNews
drugs.com — “Positive benefit-risk profile of laquinimod sustained in Phase II extension study 52 percent reduction (p 0.0006) in mean number of gadolinium-enhancing (GdE) T” View full resource at drugs.com
Most Recently Shared on September 21, 2010 at 7:15 pm By:
Drugs and Devices OW OW Health
Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis: Positive bene... http://bit.ly/9s9IiE #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
HCPLive
Your online destination for Neurology news,events,and resources
-
Bob Finn - Medical News Net
Bringing you the latest news from scientific meetings and the policy world. Check us out at www.internalmedicinenews.com
-
Doctors Lounge
DoctorsLounge medical community, news, discussions and blogs.
Advertisement
